The administration of obestatin at all doses used partly reversed the colitis-evoked increase in mucosal concentration of IL-1β, and this effect was statistically significant after obestatin administered at doses of 8 or 16 nmol/kg (Figure 5). Here, IL1B is linked to colitis.